9月26日 - ** 药物开发商 Fractyl Health GUTS.O股价盘前上涨 24.7% 至 1.26 美元
** 该公司称， (link)，接受其试验性主导产品Revita治疗的患者在停用GLP-1药物后体重仍能保持下降。
** Revita是一种门诊内窥镜手术，旨在通过水热消融改变小肠部分的功能障碍，从而恢复代谢健康。
** 在停用礼来公司LLY.N肥胖症特效药Zepbound的活性成分tirzepatide后3个月，接受Revita治疗的患者体重增加了2.5%，而接受假手术的患者体重增加了10
** 截至最后收盘，股价累计下跌51
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.